A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

A new research perspective was published in Oncotarget's Volume 15 on September 4, 2024, entitled, “Trained and ready - the ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

Relapsed acute myeloid leukemia (AML ... and each person’s case is different. One 2021 study of adults who experienced their first AML relapse after 5 years of remission found the median ...

Student 1 is an unintelligible female speaker with a very limited phonetic repertoire, severe pitch and loudness problems and little residual hearing. During 12+ years of speech therapy prior to entry ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

An international team of scientists has uncovered a mechanism by which acute ... of leukemia cells that could potentially be therapeutically targeted in AML." Previous studies have shown that ...

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

A four-year, $1.2 million grant from the National Cancer Institute of the National Institutes of Health may help researchers ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...